Category: Biopolar

AstraZeneca announced the online publication of long-term SEROQUEL® (quetiapine fumarate) clinical trial data in the Journal of Affective Disorders. Results show that SEROQUEL in combination with lithium or divalproex significantly increased the time to recurrence of any mood event in patients with bipolar I disorder compared with lithium or divalproex alone.

Share and Enjoy:
These icons […]

Repligen Corporation (Nasdaq: RGEN) announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder later this year. This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately […]

Psychiatrists have cautioned against the use of antidepressants alone in people with bipolar disorders, saying they could worsen a patient’s condition by causing a destabilisation in mood.

Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.

A study from the Massachusetts General Hospital (MGH) supports previous reports that adolescents with bipolar disorder are at increased risk for smoking and substance abuse. The article appearing in the June Drug and Alcohol Dependence - describing the largest such investigation to date and the first to include a control group - also indicates that […]

New findings from research supported by NARSAD, the world’s leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception — the behaviors associated with many psychiatric illnesses, such as schizophrenia, bipolar disorder and depression.

Share and Enjoy:
These […]

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY® (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of Schizophrenia […]

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the […]

Most people believe that the way we see things is affected by how we feel emotionally. Does our mood really change what we see or do individuals with certain genetic traits always tend to see things differently, regardless of their mood? Earlier research suggested that people with bipolar mood disorder might alternate their perception more […]

Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts # […]

A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM-IV (SCID).

Share and Enjoy:
These icons link to social bookmarking sites where readers can […]